Is the business good?
How good a business is SUPN?
Supernus Pharmaceuticals, Inc. earns −5.3% on the capital it employs against a 9.0% cost of capital, so growth costs more than it returns.
−5.3%
Return on invested capital · cost of capital 9.0% · 14 points below what the capital costs: growth destroys value
- Operating margin
- −7.8%
Operating margin · Drug Manufacturers - Specialty & Generic median 12% · 12 months to Q1 2026
- Share count, year on year
- +3.2%
Share count, year on year · shareholders own a smaller slice than a year ago
- R&D as % of revenue
- 15%
R&D as % of revenue
| Year | Operating margin |
|---|---|
| FY2020 | 33% |
| FY2021 | 15% |
| FY2022 | 6.9% |
| FY2023 | −0.87% |
| FY2024 | 12% |
| FY2025 | −8.7% |
Details›
- Gross margin12 months to Q1 2026
- 89%
- Operating margin12 months to Q1 2026
- −7.8%
- Net margin12 months to Q1 2026
- −3.7%
- Free cash flow margin
- 11%
- R&D as % of revenue
- 15%
- Revenue, trailing twelve months
- $777M
- Free cash flow, trailing twelve months
- $82M
- Net income, trailing twelve months
- −$29M
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- −5.3%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion from the cash flow statement.
Drug Manufacturers - Specialty & Generic
Ranks #19 of 28 by Smart Score